硫酸阿托品舌下含服治疗儿童及青少年脑瘫流涎症
Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy.
作者信息
Dias Bruno L Scofano, Fernandes Alexandre R, Maia Heber de S
机构信息
Rede SARAH de Hospitais de Reabilitação; Rio de Janeiro RJ, Brasil.
Universidade Federal Fluminense; Niterói RJ, Brasil.
出版信息
Arq Neuropsiquiatr. 2017 May;75(5):282-287. doi: 10.1590/0004-282X20170033.
OBJECTIVE
To report the effect of sublingual atropine sulfate to treat drooling in children with cerebral palsy by comparing the results of the Drooling Impact Scale in a non-controlled open clinical trial.
RESULTS
Twenty-five children were assessed. The difference in the mean scores of the pre- and post-treatment scales reached statistical significance. There was a low frequency of side effects compared to studies with other anticholinergics.
CONCLUSION
The use of sublingual atropine sulfate seems to be safe and there is a reduction in the Drooling Impact Scale score, which suggests efficacy in the treatment of drooling in children and adolescents with cerebral palsy. Our results should be replicated in randomized, placebo-controlled studies with larger numbers of participants.
目的
在一项非对照开放性临床试验中，通过比较流涎影响量表的结果，报告硫酸阿托品舌下含服治疗脑瘫患儿流涎的效果。
结果
对25名儿童进行了评估。治疗前后量表平均得分的差异具有统计学意义。与其他抗胆碱能药物的研究相比，副作用发生率较低。
结论
硫酸阿托品舌下含服似乎是安全的，流涎影响量表得分有所降低，这表明其对治疗脑瘫儿童和青少年的流涎有效。我们的结果应在更大样本量的随机、安慰剂对照研究中得到重复验证。
Zotero 插件